Adamas Trust, Inc. - 9.250% Senior Notes Due 2031 (ADAMO)
Live price chart, market sentiment, and community perspectives for Adamas Trust, Inc. - 9.250% Senior Notes Due 2031 (NASDAQ: ADAMO).
Live price chart, market sentiment, and community perspectives for Adamas Trust, Inc. - 9.250% Senior Notes Due 2031 (NASDAQ: ADAMO).
On our desk, we are closely tracking the pricing behavior and liquidity of Adamas Trust's 9.250% senior notes due 2031 (ADAMO). With the offering structured around a $90 million base and a 30-day over-allotment option, sentiment remains neutral. Traders are watching how these fixed-rate notes integrate into the broader capital stack alongside the company's subsequent 9.600% notes issuance later in the year. The valuation reflects stable market absorption, but macro real estate credit headwinds mean we are maintaining a disciplined, balanced posture without overcommitting capital.
Looking at the structural debt profile reported in the filings, Adamas Trust operates with significant leverage, with total consolidated indebtedness hovering around $11.4 billion. While the senior unsecured notes offer an attractive fixed coupon of 9.250% maturing in April 2031, investors must account for their structural subordination to secured and subsidiary-level debt. The inclusion of a 101% cash repurchase right upon a defined Change of Control Repurchase Event provides a baseline layer of protection, but overall credit risk requires careful monitoring of the mortgage REIT's underlying residential and mortgage credit asset performance.
When analyzing the technical signals for ADAMO on the Nasdaq, the indicators point toward a consolidating pattern. With the RSI hovering around 44.39 and an ADX indicating moderate trend strength, the notes are currently locked within a tight Bollinger Band range. Quantitative models suggest waiting for a decisive breakout or volume catalyst before adjusting duration risk. Analysts evaluating execution timing should pay close attention to the T+5 or T+3 settlement protocols outlined in the respective pricing term sheets and ensure compliance with SEC Rule 433 disclosure requirements.
Explore plasma cleansing, somatic organ swaps, and BCI.